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A B S T R A C T
Objective: The objective of this study was to understand the effect of acetylsalicylic acid (aspirin) on resistance arteries from mesentery and uterus. During pregnancy,
the uterine vasculature undergoes consistent growth to provide sufficient uteroplacental blood flow, a process whose failure is associated with pregnancy compli-
cations characterized by high uterine vascular resistance.
Methods: Uterine arcuate (UA) and mesenteric arteries (MA; diameter< 300 µm) isolated from non-gravid, mid-gravid (day 14), and late-gravid rats (day 20) were
exposed to aspirin (10−12 to 10−5M). Further, in UA from late-gravid rats, aspirin was evaluated in presence of inhibitors of nitric oxide synthases, cyclooxygenase,
cyclic nucleotides (cAMP, cGMP) and BK channels, and also on endothelium-denuded vessels.
Results: Aspirin dilated both UA and MA in a dose dependent manner. Pregnancy increased aspirin vasodilation in MA and UA from mid-gravid rats, an effect that
was reduced in vessels from late gravid animals at concentrations> 10−7 M. Further, uterine vasodilation was significantly reduced when the endothelium was
removed (p < 0.001), and by inhibitors of nitric oxide synthase (p < 0.001), cyclooxygenase synthase (p < 0.05), cyclic nucleotides cGMP/cAMP and BK
channels.
Conclusion: This is the first study to show a direct vasodilatory effect of aspirin on rat uterine artery that is mediated by a combination of cellular – primarily
endothelial - mechanisms. Our results in UA suggest that the use of aspirin may be effective in enhancing uteroplacental blood flow, while its vasodilation effect on
MA may lower peripheral resistance.
1. Introduction
Acetylsalicylic acid, best known by its first trade name aspirin, is
one of the oldest and most frequently used drugs in the world. Aspirin
has multiple physiological effects, one of which is the inhibition of ei-
cosanoid biosynthesis [1], making it highly important in cardiovascular
and anti-inflammatory treatments. Aspirin is a nonsteroidal anti-in-
flammatory drug (NSAID), but unlike other NSAIDs, it does not increase
the risk of hypertension [2,3], on the contrary, it causes slight decrease
in blood pressure [3–5]. By acetylating cyclooxygenases (COX) it pre-
vents COX binding to arachidonic acid (AA), which inhibits the pro-
ductions of prostanoids such as prostacyclins and thromboxane A2 [6].
It has also been shown that aspirin by acetylating endothelial nitric
oxide (NO) synthase [7] enhancing the production of NO [8], therefore,
may have a positive effect in preventing cardiovascular diseases.
Numerous clinical trials have been carried out, supporting the idea
that low-dose aspirin may be helpful for pregnant women at high risk of
developing preeclampsia (PE) and intrauterine growth restriction
(IUGR) [9–12]. These pregnancy complications, PE and IUGR, affect
pregnant women world-wide and are a major cause of maternal and
perinatal mortality and morbidity. One of the complications that
characterizes PE and IUGR is increased uterine vascular resistance as-
sociated with endothelial dysfunction.
Because reduced uteroplacental blood flow is a hallmark of both PE
and IUGR, we hypothesized that aspirin may have direct vasodilatory
actions on the uterine circulation, particularly on small resistance ar-
teries. The results confirm this hypothesis and suggest that this drug
could alleviate pregnancy complications associated with increases in
uterine artery resistance, such as PE and IUGR.
2. Materials and methods
2.1. Materials
The physiological salt solution HEPES-PSS was freshly prepared for
each experiment and comprised of: NaCl (141.8mM), KCl (4.7 mM),
MgSO4 (1.7mM), EDTA (0.5 mM), CaCl2 (2.8mM), HEPES (10.0 mM),
KH2PO4 (1.2 mM), Glucose (5.0mM). The pH was adjusted to 7.40 at
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37.0 °C with 10M NaOH.
Chemicals: phenylephrine, Nω-nitro-L-arginine methyl ester (L-
NAME), indometachin, paxillin, 1H-(1,2,4)oxadiazolo[4,3-a]quinox-
alin-1-one (ODQ) and, 9-(Tetrahydro-2-furanyl)-9H-purin-6-amine (SQ)
were purchased from Sigma-Aldrich (Milan, Italy).
Acetylsalicylic acid (aspirin, Rhodine® 3118) was kindly provided
by Novacyl, Lyon, France.
2.2. Animals & approvals
Sprague-Dawley female rats, 12–14weeks old, were used in all ex-
periments. Rats were housed at a temperature-controlled condition of
22 °C ± 2 °C and under a 12-hour light/dark cycle; food and water
were provided ad libitum. Females were bred overnight in isolated pairs
by the placement of a male rat. The first day of pregnancy was con-
firmed by the presence of a seminal plug on the following morning.
This study was approved by the local ethical committee at the
University of Calabria and the Italian Ministry of Health. All experi-
ments were conducted in accordance with the ‘3R principles’ (www.
nc3rs.org.uk) to reduce the number of animals and to optimize ex-
perimental protocols for obtaining maximum data from each tested
animal, and with the European Guidelines for the care and use of la-
boratory animals (Directive 2010/63/EU).
2.3. Vasodilation evaluation
Uterine arcuate arteries (UA, diameter< 300 µm)) and third order
mesenteric arteries (MA, diameter< 300 µm) were obtained from age-
matched non-gravid (NP), mid-gravid (P14, 14 days after conception)
and late-gravid (P20, 20 days after conception) rats. Following eu-
thanasia by isoflurane and decapitation, the abdominal cavity was
opened, and the uterus with its vasculature and the entire mesentery
were excided and placed in a Petri dish containing cold (4 °C) physio-
logical HEPES salt solution (HEPES-PSS). Arterial segments (1–2mm
long) were dissected free from connective and adipose tissue and
transferred to the chamber of a small-vessel arteriograph. One end of
the vessel was tied onto a glass cannula and flushed of any luminal
contents by increasing pressure using a servo-null pressure system
(Living Systems Instrumentation) prior to securing the distal end onto a
second cannula.
All vessels were continuously superfused with HEPES-PSS at 37 °C
and pH 7.4, pressurized to 50mmHg and equilibrated for 45–60min
before beginning experimentation. Lumen diameter was measured by
trans-illuminating each vessel segment, and using a video dimension
analyzer (Living Systems Instrumentation) in conjunction with data-
acquisition software (Ionoptix) to continuously record lumen diameter.
Following equilibration, all vessels were pre-constricted with pheny-
lephrine to produce a 40–50% [13] reduction in baseline diameter.
Once constriction was achieved and the tissue was stable for about
10min, aspirin was added in increasing concentration from 10−12 to
10−5M while continually measuring changes in lumen diameter using a
video dimension analyzer (Living Systems Instrumentation).
In some vessels, the endothelium was removed by air perfusion
prior to equilibration, and the effectiveness of this procedure was
confirmed by the absence of dilatation to acetylcholine (10–5 M).
2.4. Mechanism determination
The mechanism of action was investigated using the following
pharmacological inhibitors: Nω-nitro-L-arginine methyl ester (L-NAME,
2× 10−4M) for nitric oxide synthase (NOS), Indomethacin (10−5M)
for COX, paxilline (10−5M) for BKCa channel, 1H-(1,2,4)-oxadiazolo-
[4,3-a]-quinoxalin-1-one (ODQ, 10−5M) for guanylate cyclase and 9-
(Tetrahydro-2-furanyl)-9H-purin-6-amine (SQ, 10−5M) for adenylate
cyclase. Vessels were pre-incubated with inhibitors for 20min before
pre-constriction with phenylephrine and the addition of aspirin.
2.5. Statistics and calculations
In pressurized arteries, vasodilation to aspirin was expressed as
percent of maximal diameter which was determined at the end of each
experiment by the addition of a relaxing PSS solution containing dil-
tiazem (10 µM) and papaverine (100 µM).
Data are expressed as means ± SEM, where n is the number of
arterial segments studied.
Data were analyzed for normal distribution by Shapiro-Wilk test.
Differences in responses between groups were determined by one-way
ANOVA with Sidak’s multiple-comparisons tests or by Student’s t-test,
as indicated in figure legends. p values ≤0.05 were considered statis-
tically significant.
3. Results
Aspirin induced vasodilation in UA isolated from both NP and P20
rats (Fig. 1). In NP rats the effect was concentration-dependent over the
studied range (from 10−12M to 10−5M), with 75% of maximal vaso-
dilation evident at the highest concentration. UA from P20 rats were
more sensitive to aspirin at low concentrations, with a maximum va-
sodilatation of 40% up to 10−7M; the effect decreased thereafter, and
was only about 10% at 10−5M, a significant reduction (p < 0.05)
compared to the effect in NP rats.
UA from P14 rats showed a response to aspirin that was very similar
to that in NP rats (Fig. 2) while, compared to vessels from P20 animals,
the response was significant different (p < 0.05) at concentrations
higher than 10−7M.
To investigate whether the effect of aspirin was dependent on the
type of vascular bed, aspirin was also tested on similarly-sized MA. The
results in MA showed that aspirin induced a concentration-dependent
vasodilation in both NP and P20 rats with a maximum vasodilatation of
20% and 60%, respectively (p < 0.001; Fig. 3).
To study the mechanism behind this effect in UA from P20 rats, a
single intermediate concentration (10−10M) that produced maximal
vasodilation was used. As shown in Fig. 4, the absence of the en-
dothelium significantly reduced the effect of aspirin (p < 0.001).
When aspirin was tested in presence of L-NAME, a NO inhibitor, or
indomethacin, a COX inhibitor, vasodilation was also reduced sig-
nificantly (p < 0.001 and p < 0.05, respectively, as shown in Fig. 5).
The results show that aspirin-induced vasodilation is highly dependent
on NO.
As shown in Fig. 6, the effect of aspirin was also inhibited by the
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Fig. 1. Effect of Acetylsalicylic acid on uterine artery from non-gravid and late-
gravid rats. Acetylsalicylic acid was tested on uterine arteries isolated from non-
gravid (NP) and late-gravid rats (P20). Data are reported as Means ± SEM,
n=number of experiments. Statistical analysis was performed using one-way
ANOVA with Sidak’s multiple-comparisons tests, *p < 0.05.
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cGMP inhibitor ODQ (50%, p < 0.05) and the cAMP inhibitor SQ
(82%; p < 0.01) respectively. Furthermore, in presence of paxillin, a
high-conductance Ca2+-activated potassium channel (BKCa) inhibitor,
vasodilation was reduced about 50% (p < 0.05, Fig. 7).
4. Discussion and conclusion
Our data show that aspirin induced a concentration-dependent va-
sodilation in UA, particularly in vessels from NP and P14 rats. While
aspirin induced significant vasodilation at low concentrations (up to
10−7M) in P20 rats, this effect declined significantly at higher con-
centrations. Interestingly, at the highest concentration of 10−5M va-
sodilation was 6 times lower in P20 compared to NP and P14.
To find out if the effect of aspirin was specific to the uterine cir-
culation, we exposed aspirin on MA from the splanchnic circulation,
which accounts for about 40% of total peripheral resistance. Aspirin
was also found to induce a concentration –dependent vasodilatation in
MA and this effect was increased significantly in vessels from P20 rats,
indicating that aspirin has a more pronounced effect in late-pregnancy,
as compared to the non-pregnant condition.
In NP rats, aspirin induced a concentration-dependent vasodilation
in both UA and MA, with a greater effect on UA (60–70%) than MA
(20%). In P14 rats, the effect on UA was similar to that of NP rats. In
P20 rats, the effects of aspirin on UA faded at higher concentrations,
contrary to MA, where it increased significantly. This difference in
sensitivity of UA vs. MA to aspirin is highly dependent on whether the
rats are pregnant or not. This differential response might be explained
by the fact that the splanchnic and reproductive systems undergo dif-
ferent changes during pregnancy, e.g. the uterine vasculature, in par-
ticular, becomes less sensitive to vasodilators and undergoes consider-
able expansive remodeling [14]. Based on our results aspirin may,
therefore, be beneficial to the cardiovascular system during pregnancy
by increasing uteroplacental blood flow and lowering peripheral






















Fig. 2. Effect of Acetylsalicylic acid on uterine artery from non-gravid, mid-
gravid and late-gravid rats. Acetylsalicylic acid was tested on uterine arteries
isolated from non-gravid (NP), mid-gravid (P14) and late rats (P20). Data are
reported as Means ± SEM, n=number of experiments. Statistical analysis was
performed using one-way ANOVA with Sidak’s multiple-comparisons tests,
*p < 0.05.




















Fig. 3. Effect of Acetylsalicylic acid on mesenteric artery. Acetylsalicylic acid
was tested on mesenteric arteries isolated from non-gravid (NP) and late-gravid
rats (P20). Data are reported as Means ± SEM, n= number of experiments.
Statistical analysis was performed using one-way ANOVA with Sidak’s multiple-




































Fig. 4. Acetylsalicylic acid vasodilation is endothelium dependent.
Acetylsalicylic acid at 10−10M was tested on entire uterine arteries (control)
and on uterine arteries without endothelium (denuded) isolated from late-
gravid rats. Data are reported as Means ± SEM, n= number of experiments.















































Fig. 5. Acetylsalicylic acid vasodilation is NOS and COX dependent.
Acetylsalicylic acid at 10−10M was tested on entire uterine arteries isolated
from late-gravid rats in absence (control) and in presence of the NOS inhibitor
(L-NAME) or the COX inhibitor (indomethacin). Data are reported as
Mean ± SEM, n=number of experiments. Statistical analysis was performed
using Student’s t-test, *p < 0.05, ***p < 0.001.
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resistance and blood pressure through its effects on resistance arteries
from the uterine and splanchnic circulations, respectively.
Our results are particularly interesting in the light of a recent
multicenter clinical study called ASPRE, showing that the administra-
tion of aspirin before week 16 of gestation to pregnant women at risk of
developing PE prevents these women from developing preterm PE [15].
The maternal uterine circulation is a unique vascular bed that under-
goes substantial vasodilation and growth during pregnancy [16] to
provide adequate placental perfusion for normal fetal growth and
pregnancy outcome. Failure of uterine vasculature adaptation to preg-
nancy increases the risk for maternal and fetal diseases such as pre-
eclampsia and IUGR [17,18]. Our results show that aspirin-induced
vasodilation of small UAs is dependent on both gestational age and
concentration. This is in accordance with the ASPRE study [19] and a
study from 2010, where Bujold et al. [9] evaluated clinical data on low-
to mid- dose aspirin using meta-analysis, and showed that when the
women started treatment on or before week 16, the risk of having PE or
IUGR was significantly lowered compared to those who started aspirin
administration after week 16. Furthermore, several clinical studies have
shown that low-dose aspirin reduces uteroplacental vascular impedance
in gestation [10,20].
Our results also correlate with the aspirin dosage recommendations,
as the concentration of 10−7 100–150mg/day a dose suggested for
treatment in women at risk for PE [15].
Although clinical studies have shown positive effect of aspirin on
the uterine circulation, the exact pharmacological mechanisms remain
elusive. Our results indicate that vasodilation induced by aspirin was
reduced more than 80% when the endothelium was removed, sug-
gesting that the effect is highly endothelial-dependent.
Inhibition of COX with indomethacin resulted in about a 40% re-
duction compared to control. This was surprising, since aspirin is
known to inhibit COX, but perhaps the aspirin concentration tested was
a too low dose for complete inhibition. In addition, a recent study
showed a significant increase in UA COX in pregnant rats treated with
low dose of aspirin [21], thus, this enzyme may be upregulated under
these conditions, requiring higher aspirin levels for complete inhibition.
Activation of COX likely contributes to aspirin-induced vasodilation
through the production of prostacyclin.
The aspirin-induced vasodilation seems to be largely mediated by
NO, as inhibition of NOS reduced the effects of aspirin by 80%, quan-
titatively similar to endothelial removal. NO is known to be a potent
vasodilator of smooth vascular muscle via cGMP and other mechan-
isms, and plays a crucial role in pregnancy. In normal pregnancies the
UA endothelium increases the production of NO compared to women
who are not pregnant, while in women who develop PE, a reduction in
NO signaling has been noted in a number of studies [22–24]. This raises
the possibility that low-dose aspirin treatment can make up for the
reduction in NO signaling that occurs in PE, and enhance vasodilation
and uteroplacental blood flow.
In addition to COX and NOS inhibition, the inhibition of the cyclic
nucleotides cGMP and cAMP reduced the vasodilatation induced by
aspirin on UA in P20 rats by 50% and 75%, respectively. cAMP and
cGMP act as second messengers and play an important role in reg-
ulating smooth muscle relaxation. It has been shown that in pregnancy
the UA endothelium responds to cAMP by stimulating gap junction
which enhances vasodilation [25] and regulating NO synthesis [26]. As
already mentioned, it is also well known that vasodilation to NO in-
volves increased smooth muscle cGMP an effect that underlies the
utility of phosphodiesterase-5 inhibitors, which has also shown to be
helpful in treating PE [27,28].
Finally, inhibition of BK channels was found to inhibit aspirin va-
sodilation by 50%. Since BK channels may be regulated by PKG, this
observation further supports the primary importance of the NO/cGMP/
BK mechanism in mediating the vasodilatory effects of aspirin on UA.
Aspirin has a very short half-life in the body (15–20min) and is very
rapidly hydrolyzed to salicylic acid (SA) [29]. We found that SA was
also able to induce UA vasodilatation (data not shown), very similar to
aspirin. That is interesting, since SA does not acetylate COX, and un-
derlines the fact that aspirin-induced vasodilation is a complex me-
chanism mediated by several endothelial factors such as NO and pros-
tacyclin acting upon vascular smooth muscle.
Other studies on different types of arteries have reported vasodila-
tion induced by aspirin [30,31] but this is the first study to show a
direct effect of aspirin on resistance UA, and to provide evidence for its
mechanism being primarily endothelial-dependent and multifactorial in
nature.
In summary, we show a powerful vasodilatory effect of aspirin on






































Fig. 6. Acetylsalicylic acid vasodilation is cyclic nucleotides dependent.
Acetylsalicylic acid at 10−10M was tested on entire uterine arteries, isolated
from late-gravid rats, in absence (control) and in presence of the cGMP inhibitor
(ODQ) or the cAMP inhibitor (SQ). Data are reported as Mean ± SEM,
n= number of experiments. Statistical analysis was performed using Student’s



































Fig. 7. Acetylsalicylic acid vasodilation is BK channels dependent.
Acetylsalicylic acid at 10−10M was tested on entire uterine arteries isolated
from late-gravid rats in absence (control) and in presence of the BK channels
inhibitor (paxillin). Data are reported as Mean ± SEM, n= number of ex-
periments. Statistical analysis was performed using Student’s t-test, *p < 0.05.
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used drug for the prevention of PE worldwide. The main manifestation
of the disease is its negative effect on the overall vascular system, and
our results support the rationale of using aspirin as a prophylactic
treatment for women in risk for developing PE. Although it was beyond
the scope of this study, it would be interesting to test low dose aspirin
on UA isolated from pregnancies complicated by PE or IUGR to evaluate
its vasodilatory effectiveness on vessels in the setting of gestational
disease.
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